Switch theme
Sign up to access all valuation multiples
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
1995
58
LTM Revenue $120M
LTM EBITDA $14.4M
$16.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Assertio Therapeutics has a last 12-month revenue (LTM) of $120M and a last 12-month EBITDA of $14.4M.
In the most recent fiscal year, Assertio Therapeutics achieved revenue of $125M and an EBITDA of $6.9M.
Assertio Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Assertio Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $120M | XXX | $125M | XXX | XXX | XXX |
| Gross Profit | $83.3M | XXX | $85.7M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | $14.4M | XXX | $6.9M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 6% | XXX | XXX | XXX |
| EBIT | -$25.3M | XXX | -$18.8M | XXX | XXX | XXX |
| EBIT Margin | -21% | XXX | -15% | XXX | XXX | XXX |
| Net Profit | -$25.2M | XXX | -$21.6M | XXX | XXX | XXX |
| Net Margin | -21% | XXX | -17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Assertio Therapeutics's stock price is $1.
Assertio Therapeutics has current market cap of $63.7M, and EV of $16.2M.
See Assertio Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16.2M | $63.7M | XXX | XXX | XXX | XXX | $-0.27 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Assertio Therapeutics has market cap of $63.7M and EV of $16.2M.
Assertio Therapeutics's trades at 0.1x EV/Revenue multiple, and 2.3x EV/EBITDA.
Equity research analysts estimate Assertio Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Assertio Therapeutics has a P/E ratio of -2.5x.
See valuation multiples for Assertio Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $63.7M | XXX | $63.7M | XXX | XXX | XXX |
| EV (current) | $16.2M | XXX | $16.2M | XXX | XXX | XXX |
| EV/Revenue | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBITDA | 1.1x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBIT | -0.6x | XXX | -0.9x | XXX | XXX | XXX |
| EV/Gross Profit | 0.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.5x | XXX | -3.0x | XXX | XXX | XXX |
| EV/FCF | 0.8x | XXX | 0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAssertio Therapeutics's last 12 month revenue growth is -1%
Assertio Therapeutics's revenue per employee in the last FY averaged $2.2M, while opex per employee averaged $1.8M for the same period.
Assertio Therapeutics's rule of 40 is -147% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Assertio Therapeutics's rule of X is 10% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Assertio Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | -7% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -147% | XXX | 5% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 10% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 84% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Assertio Therapeutics acquired XXX companies to date.
Last acquisition by Assertio Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Assertio Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Assertio Therapeutics founded? | Assertio Therapeutics was founded in 1995. |
| Where is Assertio Therapeutics headquartered? | Assertio Therapeutics is headquartered in United States of America. |
| How many employees does Assertio Therapeutics have? | As of today, Assertio Therapeutics has 58 employees. |
| Who is the CEO of Assertio Therapeutics? | Assertio Therapeutics's CEO is Mr. Brendan P. O’Grady. |
| Is Assertio Therapeutics publicy listed? | Yes, Assertio Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Assertio Therapeutics? | Assertio Therapeutics trades under ASRT ticker. |
| When did Assertio Therapeutics go public? | Assertio Therapeutics went public in 1997. |
| Who are competitors of Assertio Therapeutics? | Similar companies to Assertio Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Assertio Therapeutics? | Assertio Therapeutics's current market cap is $63.7M |
| What is the current revenue of Assertio Therapeutics? | Assertio Therapeutics's last 12 months revenue is $120M. |
| What is the current revenue growth of Assertio Therapeutics? | Assertio Therapeutics revenue growth (NTM/LTM) is -1%. |
| What is the current EV/Revenue multiple of Assertio Therapeutics? | Current revenue multiple of Assertio Therapeutics is 0.1x. |
| Is Assertio Therapeutics profitable? | Yes, Assertio Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Assertio Therapeutics? | Assertio Therapeutics's last 12 months EBITDA is $14.4M. |
| What is Assertio Therapeutics's EBITDA margin? | Assertio Therapeutics's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Assertio Therapeutics? | Current EBITDA multiple of Assertio Therapeutics is 1.1x. |
| What is the current FCF of Assertio Therapeutics? | Assertio Therapeutics's last 12 months FCF is $19.7M. |
| What is Assertio Therapeutics's FCF margin? | Assertio Therapeutics's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Assertio Therapeutics? | Current FCF multiple of Assertio Therapeutics is 0.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
